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Abstract Experimental and clinical studies suggest that
gliclazide may protect pancreatic b-cells from apoptosis
induced by an oxidative stress. However, the precise mech-
anism(s) of this action are not fully understood and requires
further clariﬁcation. Therefore, using human normal and
cancer cells we examined whether the anti-apoptotic effects
of this sulfonylurea is due to its free radical scavenger
properties. Hydrogen peroxide (H2O2) as a model trigger of
oxidative stress was used to induce cell death. Our experi-
ments were performed on human normal cell line (human
umbilical vein endothelial cell line, HUVEC-c) and human
cancer cell lines (human mammary gland cell line, Hs578T;
human pancreatic duct epithelioid carcinoma cell line,
PANC-1).Toassesstheeffectofgliclazidethecellswerepre-
treated with the drug. The 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazoliumbromideassaywasemployedtomeasure
the impact of gliclazide on cell viability. Generation of
reactive oxygen species, mitochondrial membrane potential
(DWm), and intracellular Ca
2? concentration [Ca
2?]w e r e
monitored. Furthermore, the morphological changes associ-
ated with apoptosis were determined using double staining
with Hoechst 33258-propidium iodide (PI). Gliclazide
protects the tested cells from H2O2-induced cell death most
likely throughout the inhibition of ROS production. More-
over, the drug restored loss of DWm and diminished intra-
cellular [Ca
2?]e v o k e db yH 2O2. Double staining with
Hoechst 33258-PI revealed that pre-treatment with gliclazide
diminished the number of apoptotic cells. Our ﬁndings indi-
cate that gliclazide may protect both normal and cancer
human cells against apoptosis induced by H2O2.I ta p p e a r s
that the anti-apoptotic effect of the drug is most likely asso-
ciated with reduction of oxidative stress.
Keywords Apoptosis   Gliclazide   Reactive oxygen
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Introduction
Prospective clinical studies and autopsy studies show signiﬁ-
cant reduction of b-cell function and mass, respectively, in
people with type 2 diabetes mellitus (T2DM) [1]. Several
factors including hyperglycemia, hyperinsulinemia, hyperlip-
idemia, low-grade inﬂammation, and deposition of islet amy-
loid polypeptide in human pancreas have been proposed to
accountforthisdefectinT2DM[2–4].Chronichyperglycemia
leads to an increased generation of reactive oxygen species
(ROS), oxidative stress, and endoplasmic reticulum stress in a
variety of cells. In comparison with many other cell types, the
b-cells may be at exceptionally high risk of oxidative damage
and an increased sensitivity for apoptosis [5, 6].
Apart from a fundamental role of mitochondrial electron
transport chain in ROS overproduction, additional sources
of ROS may increase oxidative stress in diabetes including
glucose autoxidation, protein kinase C activation, methyl-
glyoxal formation and glycation, hexosamine metabolism,
and sorbitol formation [2, 4, 7, 8]. Recently published data
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DOI 10.1007/s11033-011-1323-zindicate, that excessive concentration of ROS in diabetes is
responsible for the activation of several intracellular sig-
nalling pathways, that may affect cell function and struc-
ture, increasing the risk of apoptosis [5, 6].
Gliclazide—a second-generation sulphonylurea—is
commonly used for the treatment of T2DM. The drug act by
stimulating insulin release from the pancreatic b-cells to
lower blood glucose. The insulin secretion is triggered by
binding of gliclazide to a speciﬁc K
? sulfonylurea receptor
subtype of ATP-sensitive potassium channels at the level of
b-cells plasma membrane (sulfonylurea receptor 1, SUR1),
which leads to its closure and subsequent opening of the
calcium channels and activation of an effector system of
insulin release [9]. The binding of gliclazide to SUR1 is
rapidly reversible in contrast to other sulphonylureas (e.g.
glibenclamide), that exhibit prolonged binding to SUR1.
Besides its hypoglycemic effect, gliclazide has been found
to possess extra - pancreatic and antioxidant properties. It
appears, that antioxidant activities are independent of any
inﬂuence on glycemic control [10, 11].
It is of concern, that the long-term use of sulphonylureas,
especially glibenclamide, may cause b-cells dysfunction and
apoptosis [1]. However, the mechanism(s) of this serious,
unwanted effect is unclear and several explanations have
been proposed. One of them is an oxidative stress that in
people with T2DM is not only related to chronic hypergly-
cemia but, it is also suggested that insulin secretagogues
may directly increase ROS generation and cause an oxida-
tive stress related in b-cell apoptosis [12]. As a consequence
of ROS overproduction and its damaging action, b-cell mass
and secretory function in T2DM patients treated with sul-
fonylurea may progressively decline. Insufﬁcient level of
insulin in the circulation is responsible for uncontroled
hyperglycemia and hyperlipidemia, which in turn cause
b-cell damage and induce apoptosis [13, 14]. According to
Rustenberg et al. this situation may create a vicious circle,
with the improvement of metabolic control being achieved
at the expense of an accelerated loss of beta cell mass [8].
Interestingly enough, it has recently been found that gli-
clazide prevented mice, rat and human pancreatic b-cells and
human endothelial cells from apoptosis [15–19]. It is sug-
gested that this action of the drug is most likely associated
with its free radical scavenging properties [20]. However,
anti-apoptotic action of gliclazide in other types of cells,
especially cancer cells, has not been explored sufﬁciently.
Therefore, the aim of our study was to check whether gli-
clazide has alsoability toprevent human normal(HUVEC-c)
and two cancer cell lines (PANC-1 and Hs578T) from
apoptosis induced by an oxidative stress. The HUVEC-c cell
lineasaoneoftypeofhumannormalendothelialcellshasnot
been explored for this purpose. We believe that PANC-1 and
Hs578T cell lines are good candidates for our study as
examples of the most common T2DM associated cancers.
Materials and methods
Chemicals
Hydrogen peroxide (H2O2) and gliclazide were obtained from
Sigma Chemicals (St. Louis, USA). Kaighn’s modiﬁcation of
Ham’s F-12 medium (F-12K), Dulbecco’s modiﬁed Eagle’s
medium (DMEM) and fetal bovine serum was supplied by
American Type Culture Collection (ATCC) (Rockville, MD,
USA). Trypsin–EDTA, penicillin/streptomycin, 20,70-dichlor-
odihydroﬂuorescein diacetate (DCFH2-DA) and 5,50,6,60-tet-
rachloro-1,10,3,30- tetraethylbenzimidazolcarbocyanine iodide
(JC-1)werepurchasedfromSigma.Fluo-4NWCalciumAssay
KitswereobtainedfromMolecularProbes(Eugene,USA).All
other chemicals and solvents were of high analytical grade and
were obtained from Sigma or POCH S.A. (Gliwice, Poland).
Cell culture and treatment
The normal cell line (human umbilical vein endothelial
cell line—HUVEC-c), and cancer cell lines (pancreatic
duct epithelioid carcinoma cell line—PANC-1 and mam-
mary gland cell line—Hs578T) were purchased from
ATCC. PANC-1 cell strain is derived from an epithelioid
carcinoma of pancreatic duct of 56 year old Caucasian
male. Chromosome studies indicate a modal number of 63
with 3 distinct marker chromosomes and a small ring
chromosome. This is a hypertriploid cell line. The Hs
578T cell strain is derived from the breast carcinoma of
74 year old Caucasian female. Cytogenetic analysis
revealed that Hs578T cell line is a hypotriploid with a
modal chromosome number of 59. This cell line does not
express estrogen receptor. All cell lines were grown as a
monolayer in standard conditions: 37C, 100% humidity,
the atmosphere being 5% CO2 and 95% air with appro-
priate growth medium: (1) HUVEC-c cell line—F-12K
medium supplemented with 0.1 mg/ml heparin and
0.05 mg/ml endothelial cell growth supplement, (2)
PANC-1 cell line—DMEM, and (3) Hs578T cell line—
DMEM supplemented with 0.01 mg/ml bovine insulin.
Complete growth media were supplemented with 10%
fetal bovine serum, penicillin (10 U/ml) and streptomycin
(50 lg/ml). In all experiments cells in logarithmic phase
of growth were used. The cells were monitored periodi-
cally for mycoplasma contamination. Cultured cells were
removed by trypsinization, resuspended in fresh medium,
centrifuged for 5 min at 2009g and plated into 96-well
plates at the density of 10
5 cells/ml (10
4 cells/well) for
3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bro-
mide (MTT), ROS, mitochondrial membrane potential
assays or on petri dishes for morphological examination
and at the density of 3 9 10
4 cells for calcium assay
according to the manufacture’s protocol. After 24 h (time
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growth phase) different concentrations of H2O2 were
added to the appropriate microplate wells or Petri dishes
and the cells were incubated in a CO2 incubator for dif-
ferent period of time (2–72 h) depending on the assess-
ment method.
In some experiments cells were pre-incubated with the
3 mM N-acetylcysteine (NAC) or different concentrations
of gliclazide (5–50 lM) for 1 h, then H2O2 at the appro-
priate subtoxic concentration (50, 100, 200 lM) was added
and incubation was continued for the required period of
time under the same conditions. After pre-treatment with
NAC or gliclazide the media were replaced with fresh ones
without NAC or gliclazide. Control cells were treated with
a corresponding volume of medium (instead of H2O2 or
antioxidants) according to the same schedule. NAC was
used as a control agent for gliclazide.
Cytotoxicity assays
The cytotoxicity of H2O2 in human tumor and normal cell
lines was measured by a standard microplate MTT color-
imetric method [21]. For this purpose 10
4 cells in 0.1 ml
culture medium were seeded to each well. After 24 h,
0.05 ml H2O2 in different concentrations (50–600 lM) was
added to appropriate wells, and cells were incubated for 24,
48 or 72 h. After incubation, 50 ll MTT at the ﬁnal con-
centration of 6 9 10
-3 M in PBS was added to each well
and the microplates were incubated in a CO2 incubator for
3 h. After aspiration of the culture medium, the obtained
formazan crystals were dissolved in 100 ll dimethyl sulf-
oxide (DMSO), the plates were mechanically agitated for
1 min, and absorbance at 570 nm was measured with a
microplate reader (Awareness Technology Inc., USA).
Cytotoxicity of the H2O2 was expressed as IC50 value,
which is the concentration of compound that reduces cell
viability by 50% relative to the control (untreated cells).
In the experiments with antioxidant, the cells were
preincubated with NAC (3 mM) or gliclazide (5–50 lM)
and then treated with 50, 100 or 200 lMo fH 2O2 for 24, 48
or 72 h. The relative number of viable cells was deter-
mined by comparing the absorbance of the treated cells
with the corresponding absorbance of untreated (control)
cells taken as 100%.
Determination of ROS level
Intracellular ROS production was determined directly in
cell monolayers in black 96-well ﬂat-bottom microtiter
plates using a Fluoroskan Ascent FL microplate reader
(Labsystems, Sweden). Cells in complete medium were
incubated with 50–200 lMo fH 2O2 for 2, 4 or 24 h in the
presence or absence of the antioxidants (3 mM NAC, gli-
clazide: 5–50 lM). To measure the production of ROS,
cells were treated with 5 lM DCFH2-DA at 37C for
30 min and the ﬂuorescence of DCF was measured at
530 nm after excitation at 485 nm (DCFH2-DA after
deacetylation to DCFH2 is oxidized intracellularly to its
ﬂuorescent derivative DCF). Assays were performed in
modiﬁed Hank’s buffered salt solution (HBSS) (140 mM
NaCl, 5 mM KCl, 0.8 mM MgCl2, 1.8 mM CaCl2,1m M
Na2HPO4, 10 mM HEPES and 1% glucose, pH 7.0).
Mitochondrial membrane potential (DWm)
Cells were seeded in 0.1 ml culture medium into black
96-well titration microplates. After 24 h, 0.05 ml H2O2
(50–200 lM) or an uncoupling mitochondrial agent chlo-
rophenylhydrazone (CCCP) in various concentrations
(0.01–10 lM) was added to appropriate wells. The cells
were incubated with H2O2 and CCCP for 2, 4 or 24 h. At
the end of H2O2 or CCCP treatment, the medium was
removed and the cells were incubated with 5 lM JC-1 in
HBSS for 30 min, at 37C, in the dark. Then the ﬂuores-
cence of both JC-1 monomers and dimers was measured on
a Fluoroskan Ascent FL microplate reader (Labsystems,
Sweden) using ﬁlter pairs of 530 nm/590 nm (dimers) and
485 nm/538 nm (monomers). JC-1 is a ﬂuorescent carbo-
cyanine dye, which accumulates in the mitochondrial
membrane in two forms (monomers or dimers), depending
on mitochondrial membrane potential. JC-1 monomers
show maximum ﬂuorescence excitation and emission at
485 and 538 nm wavelengths, respectively. Negative
potential of the inner mitochondrial membrane facilitates
the formation of dye aggregates, which results in the shift
of JC-1 monomer ﬂuorescence towards red light (from
kex = 530 nm to kem = 590 nm) [22]. Thus, the mea-
surement of the JC-1 dimer to monomer ﬂuorescence ratio
is a convenient and reliable method for estimation of
changes in mitochondrial membrane potential. Prior to
ﬂuorescence measurements and taking pictures, the cells
were washed twice with HBSS to remove the dye, which
could be adsorbed into the microplate well plastic and
disturb the measurements. The results in the ﬁgures are
shown as a ratio of dimer to monomer ﬂuorescence in
relation to the control ﬂuorescence ratio, assumed to be
100%. As a positive control for the dissipation of DWm,
cells were incubated with an uncoupling mitochondrial
agent CCCP.
The cells presented in the pictures in Fig. 5 were pre-
incubated with 25 lM gliclazide or 3 mM NAC for 1 h,
then H2O2 (200 lM) was added and incubation was con-
tinued for the next 4 h. JC-1 ﬂuorescence was photo-
graphed immediately after drug treatment.
Mol Biol Rep (2012) 39:5253–5267 5255
123Monitoring of apoptosis and necrosis
The appearance of apoptotic and necrotic cells was moni-
tored by double staining with Hoechst 33258 and propi-
dium iodide using a ﬂuorescence microscopy (Olympus
IX70, Japan; magniﬁcation 4009). After 24, 48 or 72 h
treatment of cells with 200 lMo fH 2O2, the cells were
removed from the culture dishes by trypsinization, centri-
fuged and suspended in PBS at the concentration 10
6 cells/
ml. 1 ll Hoechst 33258 (0.13 mM) and 1 ll PI (0.23 mM)
were added to 100 ll of cell suspension. After 10 min of
incubation at room temperature in the dark, the cells were
dropped onto microscopic slides and examined. When
antioxidants were included the cells were ﬁrstly incubated
with 3 mM NAC or 25 lM gliclazide for 1 h, and then
with a H2O2 for additional 24, 48 or 72 h. The cells were
classiﬁed on the basis of their morphological and staining
characteristics as: live (mate blue ﬂuorescence), early
apoptotic cells (intensive bright blue ﬂuorescence), late
apoptotic cells (blue-violet ﬂuorescence) and necrotic (red
ﬂuorescence) [23]. Representative areas of cells stained at
48 h of were chosen for documentation.
Intracellular calcium measurement
Control and H2O2 treated cells were seeded into a 96-well
plate (3 9 10
4 cells in 0.2 ml culture medium per well).
After 24 h the cells were treated with H2O2 (50–200 lM)
for 4, 24, 48 or 72 h. In experiments with antioxidants,
cells were preincubated with 3 mM NAC or 5–50 lM
gliclazide for 1 h, then H2O2 was added and incubation
was continued for another 4, 24, 48 or 72 h. At the end of
incubations the medium was removed in order to eliminate
sources of baseline ﬂuorescence (the cells were washed
twice with PBS). Subsequently cells were incubated with
dye loading solution (Fluo-4 NW dye, probenecid, assay
buffer—19 HBSS, 20 mM HEPES), which were processed
according to the Fluo-4 NW Calcium Assay Kit protocol
supplied by the manufacturer (Molecular Probes) and
incubated for 30 min in the dark at 37C, and then for
another 30 min at the room temperature. The measurement
was done on Fluoroskan Ascent FL microplate reader
(Labsystems, Sweden) using 494 nm excitation and
516 nm emission wavelengths.
Statistical analysis
Data are expressed as a mean ± SD. Analysis of ANOVA
variance with a Tukey post hoc test was used for multiple
comparisons. All statistics were calculated using the
STATISTICA program (StatSoft, Tulsa, OK, USA). A
P value of\0.05 was considered signiﬁcant.
Results
Cytotoxicity studies
The cytotoxic activity of hydrogen peroxide was deter-
mined by the MTT test after 24,48 and 72 h (Table 1).
The highest cytotoxicity of H2O2 was observed after
72 h of incubation. The IC50 values of H2O2 after 72 h
of treatment were 343 lM, 433 lM and 482 lMf o r
normal cell line (HUVEC-c), breast (Hs578T) and pan-
creatic cancer cell line (PANC-1), respectively (Table 1)
(P B 0.005). Thus, the Hs578T cells and PANC-1 cells
were about 1.3 and 1.4 fold more resistant to the H2O2
than the normal cells (HUVEC-c). To discriminate the
differences between early and the late effects of H2O2
action, the investigated cell lines were exposed to
increasing hydrogen peroxide concentrations for 24, 48
and 72 h. The results revealed the marked differences
between 24 and 72 h of incubation. As shown in Fig. 1,
24 h of incubation with toxic (600 lM) concentration of
H2O2 reduced a viability of tested cells to about 50% in
relation to 72 h exposure (30% of control) (P B 0.05).
A comparison of cell viability after 24 and 72 h treat-
ment with H2O2 revealed that the duration of treatment is
an important factor for H2O2 cytotoxic effects. Experi-
mental data indicate that nontoxic concentration of H2O2
(50–200 lM) should be used to explore the effect of
gliclazide on early apoptotic changes [15, 19]. Table 2
presents, that pre-treatment of all type of cells with NAC
(3 mM) or gliclazide (5–50 lM) followed by H2O2
(50 lM) treatment improved cell viability by about
100%. Gliclazide used in the entire range of concentra-
tions increased viability after exposure to hydrogen
peroxide (200 lM) to 90% regardless of the type of cell
line.
Table 1 Cytotoxicity of H2O2
in HUVEC-c, Hs578T and
PANC-1 cell lines
The values are the mean ± SD
of 3–4 independent experiments
*P\0.005
IC50 [lM] values determined by the MTT test
Cell line 24 h 48 h 72 h
HUVEC-c 885.11 ± 0.011* 467.73 ± 0.016* 343.55 ± 0.012*
Hs578T 641.21 ± 0.009* 523.60 ± 0.019* 433.51 ± 0.013*
PANC-1 1086.42 ± 0.014* 770. 90 ± 0. 022* 481.95 ± 0.021*
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The generation of ROS was measured using the DCFH2-
DA dye. It is well documented that long-term incubation
with H2O2 (up to 72 h) may result in additional generation
of ROS due to its reaction with transient metals present in
medium (via Fenton reaction) and release of cytochrome c
which catalyzes DCFH2-DA oxidation [24]. Thus, in order
to determine ROS generation exclusively for H2O2 we
decided to measure the level of ROS at 2, 4 and 24 h.
Changes in ROS level after H2O2 treatment are shown in
Fig. 2. In all three cell lines, a gradual increase of DCF
ﬂuorescence with the increasing concentrations of H2O2
was observed at 2, 4 and 24 h after the treatment. The
kinetics of ROS formation, in relation to time of incubation
was dependent on the H2O2 concentration and the type of
cell line. At 24 h of incubation with H2O2 (200 lM), the
level of ROS in Hs578T and HUVEC-c cells increased 143
and 167%, respectively (P B 0.05). Generation of ROS did
not correlate with the sensitivity of cells to hydrogen per-
oxide. The level of ROS in PANC-1 cells was similar to
HUVEC-c cells and did not exceed 139% (P B 0.05). To
conﬁrm whether ROS are the mediator for H2O2 induced
apoptosis, the cells were treated with antioxidants. The
amounts of ROS were markedly reduced by NAC and
gliclazide. Our results showed that H2O2 increased the
level of ROS in time-dependent manner both in normal and
cancer cells, and pretreatment with NAC or gliclazide
efﬁciently protected these cells against ROS generation.
These results conﬁrm an antioxidant property of gliclazide.
Mitochondrial membrane potential (DWm)
In this study, normal HUVEC-c and cancer cells: Hs578T
and PANC-1 were stained with a ﬂuorogenic probe JC-1 to
detect changes of their mitochondrial membrane potential
after the treatment with H2O2. JC-1 has the unique property
of forming red ﬂuorescent aggregates locally and sponta-
neously under high mitochondrial potential, whereas the
monomeric form, prevalent in cells with low DWm,ﬂ u o -
rescens in green. Thus, the changes of the ratio of red/green
ﬂuorescence reﬂect the variation of DWm. ROS are
responsible for dissipation of mitochondrial potential thus, it
is reasonable to measure mitochondrial membrane potential
at the same time points as determination of the level of ROS.
Images of staining with a ﬂuorogenic probe JC-1 tested cell
lines at 4 h after treatment with 200 lMo fH 2O2 in the
presence or absence of antioxidants are presented in Fig. 3.
Figure 4 shows the accumulation of JC-1 within the
active mitochondria of the investigated cells after exposure
to H2O2. Treatment of cells with increasing concentrations
of H2O2 (50–200 lM) caused the collapse of DWm,a s
detected by the reduction of JC-1 dimer to monomer ﬂuo-
rescence ratio. Changes in DWm were dependent on both
H2O2 concentration and the length of incubation. The
highest changes were observed at 2 h of H2O2 treatment. A
200 lM concentration of H2O2 induced a drop in
Fig. 1 Number of viable HUVEC-c, Hs578T and PANC-1 cells, The
cells were treated with H2O2 (50–600 lM) for 24, 48 and 72 h, At the
end of treatment period MTT was added and cells were incubated for
an additional 3 h. Formazan crystals were dissolved in DMSO and
absorbance at 570 nm was measured with a microplate reader. Data
are the mean ± SD of 3–4 independent experiments. *P\0.05
signiﬁcant differences between drugs treated and untreated, control
cells (taken as 100%)
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123Table 2 Number of viable
HUVEC-c, Hs578T and
PANC-1 cells
The cells were preincubated
with 5–50 lM gliclazide for 1 h
at 37C. Then the cells were
treated with 50, 100 or 200 lM
H2O2 for 24, 48 or, 72 h. At the
end of treatment period MTT
was added and cells were then
incubated for an additional 3 h.
Formazan crystals were
dissolved in DMSO and
absorbance at 570 nm was
measured with a microplate
reader. Data are the mean ± SD
of 3–4 independent
experiments. *P\0.05 in
comparison to respective
control cells taken as 100%.
#P\0.05 indicates signiﬁcant
differences between H2O2-
treated cells and samples
preincubated with NAC or
gliclazide
Treatment time (h) Agent Cell line (% of viable cells)
HUVEC-c H578T PANC-1
24 H2O2 [50lM] 91.48 ± 2.953 94.65 ± 5.96 98.43 ± 4.52
NAC [3 mM] 99.78 ± 4.67 100.01 ± 5.65 98.58 ± 5.45
5 99.71 ± 5.30 102.57 ± 1.10 99.50 ± 3.00
25 gliclazide [lM] 99.53 ± 8.76 99.32 ± 5.31 100.34 ± 2.35
50 99.54 ± 5.35 101.43 ± 4.12 99.03 ± 4.20
H2O2 [100 lM] 86.50 ± 4.245 88.87 ± 3.12 92.54 ± 7.04
NAC [3 mM] 102.36 ± 5.36 99.87 ± 5.26 102.65 ± 5.87
5 97.36 ± 4.18 97.53 ± 4.90 95.62 ± 4.72
25 gliclazide [lM] 97.23 ± 2.04 98.67 ± 7.71 94.99 ± 5.99
50 95.16 ± 5.52 98.92 ± 5.00 93.78 ± 5.39
H2O2 [200 lM] 89.08 ± 6.59 76.54 ± 8.09* 83.65 ± 2.45
NAC [3 mM] 102.54 ± 4.65 97.36 ± 4.56
# 97.45 ± 5.12
5 94.87 ± 3.63 95.43 ± 5.24
# 94.89 ± 5.78
25 gliclazide [lM] 93.39 ± 4.07 96.56 ± 2.87
# 93.77 ± 2.61
50 95.01 ± 4.36 95.62 ± 9.31
# 90.78 ± 48 8
48 H2O2 [50 lM] 90.10 ± 4.87 90.43 ± 4.56 96.32 ± 5.56
NAC [3 mM] 101.27 ± 2.93 100.33 ± 3.87 100.11 ± 4.57
5 99.27 ± 4.32 99.87 ± 3.43 100.11 ± 4.32
25 gliclazide [lM] 97.21 ± 6.87 98.43 ± 4.56 99.21 ± 5.37
50 98.12 ± 2.33 101.01 ± 6.71 101.33 ± 6.71
H2O2 [100 lM] 83.45 ± 4.89* 85.32 ± 7.43 87.43 ± 4.87
NAC [3 mM] 98.25 ± 6.32
# 97.19 ± 4.52 96.12 ± 3.33
5 97.12 ± 1.67
# 102.34 ± 4.56 95.27 ± 4.34
25 gliclazide [lM] 98.11 ± 2.43
# 99.99 ± 4.39
# 96.28 ± 3.28
50 96.23 ± 3.78
# 97.43 ± 2.67
# 94.33 ± 6.72
H2O2 [200 lM] 82.89 ± 1.65 72.15 ± 2.45* 80.32 ± 7.45*
NAC [3 mM] 97.34 ± 3.12
# 98.11 ± 4.18
# 97.11 ± 3.12
#
5 93.11 ± 4.57
# 94.43 ± 9.17
# 90.32 ± 2.32
#
25 gliclazide [lM] 90.12 ± 6.87
# 96.12 ± 6.32
# 90.12 ± 4.371
#
50 89.43 ± 4.36
# 94.77 ± 4.87
# 90.18 ± 7.17
#
72 H2O2 [50 lM] 87.87 ± 5.01 90.42 ± 4.59 97.11 ± 1.44
NAC [3 mM] 98.78 ± 6.89
# 97.89 ± 4.95 99.89 ± 3.89
5 98.34 ± 4.29
# 102.57 ± 0.53
# 99.50 ± 0.79
25 gliclazide [lM] 101.23 ± 2.15
# 99.32 ± 3.63 100.34 ± 2.26
50 99.95 ± 5.14
# 1010.41 ± 1.70 99.03 ± 4.92
H2O2 [100 lM] 79.64 ± 6.24* 83.77 ± 6.24 85.21 ± 3.89*
NAC [3 mM] 99.98 ± 9.08
# 100.89 ± 5.89
# 99.98 ± 7.58
#
5 88.26 ± 9.48
# 87.55 ± 7.19
# 85.15 ± 3.77
#
25 gliclazide [lM] 86.38 ± 6.66
# 86.59 ± 7.73 84.50 ± 2.73
#
50 88.43 ± 5.10
# 87.67 ± 5.52 84.93 ± 2.43
H2O2 [200 lM] 78.181 ± 1.20* 68.53 ± 6.77* 77.87 ± 8.08*
NAC [3 mM] 98.67 ± 6.98
# 102.67 ± 8.43
# 99.78 ± 4.76
#
5 94.32 ± 4.52
# 93.32 ± 5.55
# 90.62 ± 0.79
#
25 gliclazide [lM] 90.43 ± 6.25
# 95.43 ± 3.79
# 90.99 ± 2.26
#
50 88.32 ± 3.54
# 90.32 ± 6.15* 89.13 ± 4.92
#
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123mitochondrial membrane potential in HUVEC-c, Hs578T
and PANC-1 cells by 51%, 61 and 69% respectively (Fig. 4)
(P B 0.05). The prolonged incubation (4–24 h) with the
H2O2 led to an increase of mitochondrial membrane
potential. The enhancement of DWm to a level of control was
observed at 24 h in all cell lines. NAC and gliclazide pre-
treatment effectively inhibited H2O2 -induced loss of DWm
in all cell lines. Our results suggest that antioxidant action of
gliclazide in therapeutic concentrations (5–25 lM) was
comparable to NAC. Interestingly, it was observed that
higher concentrations of gliclazide evoked greater increase
in mitochondrial membrane potential level in cancer cells
than in normal human endothelial cells.
As a positive control, prior to JC-1 labeling, cells were
preincubated with CCCP, a protonophoric uncoupler of
oxidative phosphorylation, for the same period of time as
that used for H2O2 treatment. The results are presented in
Fig. 5. After 2 h incubation, 10 lM CCCP caused loss of
mitochondrial membrane potential in HUVEC-c, Hs578T,
and PANC-1 cells up to 38, 31, and 49% respectively
(P B 0.05). We observed increase in DWm at 4 h of incu-
bation with 10 lM CCCP: 49% for HUVEC-c, 47% for
Hs578T, and 58% for PANC-1 (P B 0.05). In the longest
time of incubation (24 h) with the 10 lM CCCP a gradual
increase in DWm was reported [60% for HUVEC-c, 71%
for Hs578T, and 68% for PANC-1 (P B 0.05)].
Morphological changes in H2O2 treated cell lines
The ability of H2O2 to induce apoptosis or necrosis was
evaluated by treating the cells of each cell line with a
concentration of 200 lM for 24, 48 or 72 h. Analysis was
performed immediately after H2O2 treatment. To assess the
effect of H2O2 at the single cell level directly, we used
ﬂuorescence microscopy for examination of cells stained
simultaneously with the membrane permeating and inter-
calating dye bisbenzimide Hoechst 33258 and propidium
iodide. Changes in cell morphology, typical either of
apoptosis or necrosis are presented in Fig. 6. Alterations in
the structure, size and shape of the cell nucleus were
detected 24, 48 and 72 h after the treatment with H2O2.
The maximal increase in the amount of apoptotic cells was
noted at 48 h of H2O2 treatment. After the prolonged
incubation time (72 h) we observed chromatin condensa-
tion, cell shrinkage and nuclear fragmentation as well as a
formation of apoptotic bodies. We reported that H2O2
Fig. 2 Induction of ROS by H2O2 in HUVEC-c, Hs578T and PANC-1
cells in the presence and absence of NAC or gliclazide. The cells (10
4),
seededinto96-wellmicroplates24 hbeforetheexperimentweretreated
with different H2O2 concentrations for 2, 4 or 24 h. Oxidation of 5 lM
DCFH2-DA ﬂuorescence probe was used for monitoring the produced
ROS after drug treatment. In experiments with NAC or gliclazide, cells
werepreincubatedwith3 mMNAC or5–50 lM gliclazide for 1 h,then
H2O2 was added and incubation was continued for another 2, 4 or 24 h,
The results represent mean ± SD of four independent experiments,
*P\0.05 in comparison to respective control cells taken as 100%.
#P\0.05 indicates signiﬁcant differences between H2O2-treated cells
and samples preincubated with NAC or gliclazide
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123could induce both apoptosis and necrosis in the investi-
gated cancer and normal cell lines. The number of apop-
totic and necrotic cells were dependent on the time of
incubation with H2O2 and the type of cell line. The con-
siderable higher increase in the amount of necrotic cells
was noted at 72 h after treatment of all tested cell lines
with H2O2 (data not shown). The largest apoptotic changes
were observed in HUVEC-c cell line. Pre-treatment of
tested cells with the antioxidants, NAC or gliclazide par-
tially reduced both apoptotic and necrotic cell population.
It seems that gliclazide exhibit a similar protection
compared to NAC in relation to normal as well as cancer
cells treated with H2O2.
Intracellular calcium ion concentration
To examine whether the intracellular calcium changes were
involved in apoptosis induced by H2O2, we studied the
level of calcium using the ﬂuorescence probe Fluo- 4-NW.
Our results indicate that calcium level also depends on
H2O2 concentration, the time of incubation and the type of
cells. Table 3 shows that in the tested cells H2O2 induced a
Fig. 3 Fluorescent microscopy images of a HUVEC-c, b Hs578T
and c PANC-1 cell lines at 4 h after 200 lMo fH 2O2 treatment
without or in the presence of NAC or gliclazide. In the experiments
with the antioxidants the cells were preincubated with 25 lM
gliclazide or 3 mM NAC for 1 h, then H2O2 was added and
incubation was continued for the next 4 h, mitochondria depolariza-
tion is indicated by a decrease in the red to green ﬂuorescence
intensity ratio, green ﬂuorescence of JC-1 monomers is present in the
cells areas with high mitochondrial membrane potential, while
yellow-orange ﬂuorescence of JC- dimers is prevalent in the cell
areas with low mitochondrial membrane potential. The JC-1 stained
cells were visualized under an inverted ﬂuorescence microscope
(Olympus IX70, Japan), 4009 magniﬁcation. (Color ﬁgure online)
5260 Mol Biol Rep (2012) 39:5253–5267
123Fig. 4 Changes in mitochondrial membrane potential (DWm)o f
HUVEC-c, Hs578T and PANC-1 cells seeded into black 96-well
titration microplates in the presence and absence of antioxidant-NAC
or gliclazide, The cells were treated with different H2O2 concentra-
tions for 2, 4 or 24 h. In experiments with antioxidant or gliclazide,
cells were preincubated with 3 mM NAC or 5–50 lM gliclazide for
1 h, then H2O2 was added and incubation was continued for another
2, 4 or 24 h. DWm was estimated with a ﬂuorescence dye JC-1 at the
end of incubation directly in the cell monolayers. Fluorescence ratio
of JC-1 dimers/JC-1 monomers of control was assumed as 100%, The
results represent mean ± SD of four independent experiments.
*P\0.05 in comparison to respective control cells taken as 100%.
#P\0.05 indicates signiﬁcant differences between H2O2-treated
cells and samples preincubated with NAC or gliclazide
Fig. 5 Changes in mitochondrial membrane potential (DWm)o f
HUVEC-c, Hs578T and PANC-1 cells incubated with CCCP for 2, 4
or 24 h. DWm was estimated with a ﬂuorescence dye JC-1 directly in
monolayers of cells seeded into black 96-well titration microplates.
Fluorescence ratio of JC-1 dimers/JC-1 monomers of control was
assumed as 100%. Results are presented as mean ± SD of 3–4
independent experiments. *P\0.05 in comparison to respective
control cells taken as 100%
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123signiﬁcant increase in the intracellular free calcium no
sooner than at 48 h of incubation. At this time point, the
level of intracellular calcium in the HUVEC-c, Hs578T and
PANC-1 cells, treated with 200 lMH 2O2 increased by
about 60, 36 and 20%, respectively (P B 0.005). After
72 h incubation of the cells with H2O2 the level of calcium
decreased in normal and cancer cells. The largest decrease
in calcium content was noted in HUVEC-c cell line (about
37%) (P B 0.005) and the lowest in PANC-1 cells (about
14%) (P B 0.005) compared to the values at 48 h after the
treatment. Free radical scavengers, NAC and gliclazide,
signiﬁcantly reduced H2O2-induced changes in calcium
level at 48 h of incubation in all types of cells. At 72 h,
NAC and gliclazide markedly diminished H2O2-induced
Fig. 6 Morphological changes of a HUVEC-c, b Hs578T and
c PANC-1 cell lines at 48 h after 200 lMo fH 2O2 treatment without
or in the presence of antioxidants. The cells were stained with the PI
and the DNA speciﬁc dye Hoechst 33258. In the experiments with the
antioxidants the cells were preincubated with 25 lM gliclazide or
3 mM NAC for 1 h, then H2O2 was added and incubation was
continued for the next 48 h. The cells were analyzed under an
inverted ﬂuorescence microscope (Olympus IX70, Japan) under
magniﬁcation 4009. (Color ﬁgure online)
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123Table 3 Effect of H2O2 on intracellular level of Ca
2? in HUVEC-c, Hs578T and PANC-1 cells
Treatment time (h) Agent Cell line (% of viable cells)
HUVEC-c HS578T PANC-1
4H 2O2 [50 lM] 102.22 ± 2.39 106.16 ± 12.36 102.36 ± 13.69
NAC [3 mM] 94.26 ± 1.80 98.30 ± 4.58 98.36 ± 5.68
5 99.06 ± 0.01 95.61 ± 13.3
# 97.12 ± 3.69
25 gliclazide [lM] 92.12 ± 0.01 100.98 ± 1.25 94.26 ± 6.36
50 104.18 ± 2.70 97.37 ± 1.69 93.45 ± 4.52
H2O2 [100 lM] 102.07 ± 3.58 99.22 ± 2.58 101.36 ± 3.35
NAC [3 mM] 91.20 ± 1.36 92.93 ± 4.69 102.36 ± 1.23
5 107.72 ± 5.12 87.19 ± 1.2S 96.36 ± 3.69
25 gliclazide [lM] 103.19 ± 0.04 94.78 ± 4.58 99.26 ± 3.36
50 104.65 ± 5.54 91.91 ± 3.69 93.65 ± 1.58
H2O2 [200 lM] 98.44 ± 4.12 98.00 ± 2.58 103.24 ± 1.58
NAC [3 mM] 103.27 ± 3.25 96.54 ± 5.59 102.53 ± 3.69
5 105.93 ± 2.00 90.89 ± 3.69 100.36 ± 2.58
25 gliclazide [lM] 100.67 ± 4.04 87.00 ± 4.69 96.36 ± 2.98
50 100.93 ± 1.04 93.11 ± 6.54 97.89 ± 5.45
24 H2O2 [50 lM] 94.79 ± 1.25 85.11 ± 2.45 92.36 ± 1.23
NAC [3 mM] 98.35 ± 2.36 90.13 ± 1.22 98.12 ± 2.36
5 92.12 ± 0.01 103.02 ± 372 101.32 ± 4.39
25 gliclazide [lM] 100.98 ± 2.6 103.70 ± 2.48 100.31 ± 1.58
50 100.59 ± 3.42 98.26 ± 1.54 100.01 ± 6.67
H2O2 [100 lM] 95.24 ± 2.36 90.85 ± 2.43 102.53 ± 1.36
NAC [3 mM] 104.78 ± 1.25 93.98 ± 1.42 103.21 ± 2.25
5 96.59 ± 0.03 109.41 ± 0.82 99.87 ± 6.65
25 gliclazide [lM] 106.77 ± 6.56 106.11 ± 1.37 101.3 ± 6.64
50 104.04 ± 7.37 92.60 ± 1.3 103.65 ± 2.64
H2O2 [200 lM] 98.21 ± 2.36 91.73 ± 1.33 101.23 ± 1.36
NAC [3 mM] 106.77 ± 1.36 94.54 ± 2.34 99.87 ± 554
5 96.78 ± 5.23 100.32 ± 1.51 102.36 ± 6.36
25 gliclazide [lM] 102.52 ± 7.43 102.10 ± 0.77 100.32 ± 1.36
50 106.30 ± 4.21 112.51 ± 1.48 100.02 ± 5.23
48 H2O2 [50 lM] 122.65 ± 2.36* 110.23 ± 1.36 108.23 ± 2.36
NAC [3 mM] 107.91 ± 2.54
# 96.26 ± 2.58
# 102.32 ± 5.54
5 100.27 ± 4.58
# 101.13 ± 3.65 99.36 ± 6.32
25 gliclazide [lM] 100.41 ± 4.96
# 104.81 ± 3.05 98.36 ± 6.14
50 102.68 ± 5.63
# 104.81 ± 5.28 95.3 ± 1.25
H2O2 [100 lM] 139.67 ± 6.54* 125.48 ± 3.69* 113.25 ± 5.87*
NAC [3 mM] 106.3S ± 7.41
# 97.24 ± 5.40
# 98.36 ± 7.87
#
5 100.98 ± 2.65
# 98.45 ± 6.36
# 97.54 ± 5.69
#
25 gliclazide [lM] 100 86 ± 6.32
# 99.12 ± 3.36
# 94.15 ± 4.12
#
50 95.37 ± 4.12
# 92.41 ± 1.25
# 93.65 ± 6.48
#
H2O2 [200 lM] 159.57 ± 1.23* 135.56 ± 1.25* 120.36 ± 12.54*
NAC [3 mM] 101.15 ± 6.54
# 100.10 ± 2.23
# 102.53 ± 4.38
#
5 112.52 ± 6.32
# 91.00 ± 12.57
# 102.36 ± 8.58
#
25 gliclazide [lM] 103.95 ± 4.52
# 94.64 ± 6.32
# 98.26 ± 6.36
#
50 111.49 ± 4.23
# 92.88 ± 6.54
# 98.64 ± 554
#
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123(100, 200 lM) changes in calcium level in normal cells
(P B 0.05). Only in Hs578T cells changes in calcium level
induced by 200 lMH 2O2 after 72 h of incubation were
markedly diminished by gliclazide.
In summary, H2O2 caused a signiﬁcant increase in
intracellular calcium levels after 48 h. Moreover, at the
same time the greatest apoptotic changes were observed
(Fig. 6). The ROS generation was observed already at 2 h
of H2O2 incubation. Our results indicate that ROS evoked
increased level of calcium. Pre-incubation with antioxi-
dants: NAC and gliclazide effectively decreased H2O2 -
induced ROS enhancement and diminished an increase of
cytoplasmic free calcium in all cell lines.
Discussion
It is well known that T2DM generally progresses over time
and majority of diabetics previously well-metabolically
controlled with sulfonylureas may require insulin replace-
ment therapy. It has been suggested that exhaustion or
desensitization of pancreatic b-cells by prolonged exposure
to sulphonylureas and possibly acceleration of oxidative
stress and apoptosis are major causes of secondary failure
to these oral hypoglycemic medications. The association of
glibenclamide with increased b-cell apoptosis in human
islets has been demonstrated in vitro by Meadler et al. [25].
Clinical studies indicate that early insulin treatment in
newly diagnosed T2DM patients preserved b-cell secretory
function more effectively than glibenclamide [26]. Inter-
estingly, a retrospective analysis performed by Satoh et al.
found that patients treated with gliclazide required exoge-
nous insulin support less frequently, than those treated with
glibenclamide. These observations suggest that gliclazide
but not glibenclamide may protect b-cells and thereby
delay development of a secondary failure [27]. It is worth
mentioning that gliclazide may protect against oxidative
stress-related diabetic complications since a signiﬁcantly
lower mortality for cardiovascular diseases and malignan-
cies was suggested in patients treated with gliclazide
compared to other hypoglycaemic drugs, especially sul-
phonylureas [28–30].
There are several mechanisms that may be responsible
for b -cell mass loss and dysfunction associated with sul-
fonylureas use in diabetics. ROS overproduction and dis-
equilibrium of Ca
2? homeostasis induced by sulfonylureas
seem to be involved in these processes. It was demon-
strated that glibenclamide, glimepiride and nateglinide
stimulate ROS production in the pancreatic b-cell line
MIN6 within the therapeutic concentration range in plasma
of treated patients [12, 31]. Sawada et al. have found that
these compounds-related ROS production was mediated by
a PKC-dependent activation of NAD(P)H oxidase [12].
The secreatgogues raise the intracellular Ca
2? concentra-
tion by opening of voltage-operated Ca
2? channels and
increasing Ca
2? inﬂux [32]. Since Ca
2? plays an important
Table 3 continued
Treatment time (h) Agent Cell line (% of viable cells)
HUVEC-c HS578T PANC-1
72 H2O2 [50 lM] 108.68 ± 2.36 104.36 ± 1.23 103.36 ± 3.65
NAC [3 mM] 95.39 ± 1.54 102.92 ± 3.36 102.53 ± 4.21
5 10553 ± 6.36 92.31 ± 3.65 98.65 ± 5.36
25 gliclazide [lM] 103.15 ± 4.23 97.15 ± 1.25 96.32 ± 4.65
50 102.26 ± 6.36 104.29 ± 3.164 92.36 ± 6.32
H2O2 [100 lM] 113.32 ± 1.54* 97.91 ± 3.65 105.36 ± 8.12
NAC [3 mM] 100.32 ± 16.36
# 102.56 ± 5.14 98.26 ± 6.54
5 98.261 ± 4.58
# 104.94 ± 4.87 96.54 ± 7.26
25 gliclazide [lM] 97.50 ± 6.32
# 100.42 ± 5.87 93.25 ± 5.21
50 95.65 ± 1.25
# 101.73 ± 4.56 91.25 ± 1.36
H2O2 [200 lM] 123.53 ± 1.36* 111.23 ± 2.36* 106.32 ± 2.54
NAC [3 mM] 105.32 ± 2.64
# 110.87 ± 3.65 102.51 ± 4.65
5 102.26 ± 4.65
# 97.73 ± 4.58
# 99.36 ± 6.58
25 gliclazide [lM] 105.50 ± 3.60
# 86.39 ± 9.65
# 95.36 ± 2.65
50 101.67 ± 5.45
# 95.43 ± 4.58
# 97.12 ± 6.32
The cells were treated with different H2O2 concentrations for 4, 24, 48 or 72 h. In experiments with antioxidant or gliclazide, cells were
preincubated with 3 mM NAC or 5–50 lM gliclazide for 1 h, then H2O2 was added and incubation was continued for another 4, 24, 48 or 72 h.
The results represent mean ± SD of four independent experiments. *P\0.05 in comparison to respective control cells taken as 100%,
#P\0.05 indicates signiﬁcant differences between H2O2-treated cells and samples preincubated with NAC or gliclazide
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123role in cell survival regulation, the signiﬁcant increase in
the intracellular Ca
2? concentration induced by glibencla-
mide or tolbutamide may initiate Ca
2? dependent b-cell
apoptosis [33, 34].
In our experiments, we used H2O2 which by generation
of ROS increases an oxidative stress insult that may cause
cells death [35]. Number of evidence indicates that H2O2/
ROS activate KATP
? channels and hyperpolarize the plasma
membrane potential. It has been reported that an oxidative
stress potentates the amount of ROS by stimulating mito-
chondrial ROS production. ROS are also able to trigger the
opening of the mitochondrial permeability transition pore
to an extent, that collapses the mitochondrial membrane
potential and leads to ATP depletion [15, 36, 37]. More-
over, a reduction in the mitochondrial membrane potential
(DWm) results in the release of mitochondrial Ca
2? and a
rise in cytosolic [Ca
2?] and may also contribute to cell
death [38, 39].
As we expected, H2O2 induced apoptosis in human nor-
mal and cancer cells since the cytotoxic effects of this
molecule is well known [40]. The results of our study
indicate that gliclazide reduced the number of H2O2 -related
necrotic and apoptotic cells. These ﬁndings are consistent
with the earlier reports showing, that gliclazide attenuated
apoptotic b-cell as well as endothelial cells death induced by
an oxidative stress. As was suggested by others, we believe
that this effect is most likely caused by free radical scav-
enging properties of gliclazide [15–18]. It is worth under-
lying that these unique activities of the drug are not shared
by other sulphonylureas [20, 41]. Recently, it has been
reported that glibenclamide and glimepiride, but not glicla-
zide, signiﬁcantly increased ROS production in b-cell [12].
It is suggested that several mechanisms may be responsible
for these differences. Firstly, gliclazide possesses free radi-
cal scavenging activity. Secondly, the binding of gliclazide
to SUR1 receptor is rapidly reversible in contrary to other
sulphonylureas [10, 42]. Finally, Gier et al. have found that
gliclazide may up-regulate the expression of antioxidant
enzymes (superoxide dismutase, glutathione peroxidase,
catalase). Their experiments demonstrated that enzyme
activity changes in pancreatic b-cells were dependent on
[Ca
2?] mediated via KATP channels [15]. Interestingly, the
results of our study may at least partially support these
ﬁndings because we showed that gliclazide decreased the
intracellular [Ca
2?] in tested cell lines exposed to H2O2.
Mitochondria are major intracellular source of reactive
oxygen species and play an important role in apoptotic form
of cell death [43]. As was mentioned earlier, ROS/H2O2
cause depolarization of mitochondria and local Ca
2?
release, what leads to loss of DWm, opening of mitochon-
drial permeability transition pore, damage to cell and ﬁnally
cell death [39, 44]. This effect of H2O2 was conﬁrmed in our
experiments. We observed signiﬁcant loss of DWm in all
kind of cells as early as after 2 h of exposure to H2O2.
Furthermore, we have observed an increase in the intra-
cellular free [Ca
2?]i nH 2O2-treated human normal and
cancer cell lines at 48 h of incubation. The accumulation of
ﬂuorescent dye JC-1 in mitochondria as a consequence of
changes in DWm after treatment with H2O2 was also noted.
These ﬁndings are in agreement with previous observations
[36, 44, 45]. Nakazaki et al. found, that in rat pancreatic
b-cells H2O2 led to an increase in intracellular [Ca
2?] due to
its release from cytosolic stores and increase in Ca
2? inﬂux
across the plasma membrane (through L-type Ca
2? chan-
nels) [36]. Gonzalez et al. reported that H2O2 caused loss of
DWm and an increase in intracellular [Ca
2?] in isolated
mouse pancreatic acinar cells [46]. The results of our
experiments showed that pre-treatment with gliclazide
effectively inhibits H2O2-induced loss of mitochondrial
membrane potential and signiﬁcantly decreases the level of
intracellular [Ca
2?] in tested cell lines.
Recently, it was reported that the oxidative stress and
Ca
2? homeostasis are associated with endoplasmic reticu-
lum stress (ER stress) [47]. Marchetti et al. found that both
ER stress and oxidative stress may play a prominent role in
b-cell apoptosis evoked by high glucose concentration in
islets isolated from diabetic patients [48]. Since we noted,
that gliclazide decreased the intracellular [Ca
2?]i nH 2O2-
treated cell lines, it cannot be excluded, that the drug may
protect from apoptosis not only via decreasing the level of
oxidative stress, but also the level of ER stress.
In summary, the results of our work provide an addi-
tional evidence that gliclazide may diminish oxidative
stress-related cell damage and death. Gliclazide decreases
ROS production, elevates DWm and diminishes intracellu-
lar [Ca
2?] in human normal and cancer cells exposed to
H2O2. However, further studies are needed to explore
whether the same effect occurs in T2DM patients treated
with this drug.
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